Marinus Pharmaceuticals Inc
NASDAQ:MRNS
| Market Cap (Intraday) | 75.41M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.87 |
| 50-Day MA | $8.39 |
| 200-Day MA | $8.29 |
Marinus Pharmaceuticals Inc Stock, NASDAQ:MRNS
5 Radnor Corporate Center, 100 Matsonford Road, Radnor, Pennsylvania 19087-5279
United States of America
Phone: +1.484.801.4670
Number of Employees: 165
Description
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.